Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Jan;6(1):65-73.
doi: 10.1007/BF00915366.

The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation

The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation

T F Tedder et al. J Clin Immunol. 1986 Jan.

Abstract

A panel of monoclonal antibodies and ligands that bind to the CR1 or CR2 complement receptors of B cells has been used to investigate the role of these membrane molecules in regulating B-cell proliferation and differentiation. When CR2 was modulated from the surface of B cells by treatment with the HB-5 antibody and a secondary goat anti-mouse immunoglobulin antibody, Epstein-Barr virus-induced polyclonal B-cell proliferation and immunoglobulin production were inhibited by 83 and 90%, respectively. In contrast, modulation of other cell surface molecules, HB-2, B1, and the C3b receptor (CR1), or pretreatment of B cells with C3d,g (a CR2 ligand) or HB-5 antibody, alone minimally inhibited these responses. Neither the HB-5 antibody C3d,g, nor a monoclonal antibody (YZ-1) reactive with CR1 induced resting B cells to proliferate, nor did they alter anti-mu antibody-induced proliferation. Similarly, treatment with C3d,g or with the HB-5 or YZ-1 antibodies did not induce B cells to secrete immunoglobulin or affect pokeweed mitogen-induced plasma-cell formation. Whereas CR2 appears to be the functionally relevant receptor for Epstein-Barr virus on B cells, the effects of ligand interactions with CR1 and CR2 on normal B-cell proliferation or differentiation remain unidentified.

PubMed Disclaimer

References

    1. Cell Immunol. 1977 Jun 15;31(2):225-33 - PubMed
    1. Virology. 1978 May 15;86(2):423-31 - PubMed
    1. Immunol Rev. 1979;45:41-67 - PubMed
    1. Tissue Antigens. 1984 Sep;24(3):140-9 - PubMed
    1. J Immunol. 1981 Jan;126(1):107-12 - PubMed

Publication types

LinkOut - more resources